Keytruda might be prescribed by itself or with lenvatinib (Lenvima) in this case. TNBC with PD-L1 that’s recurring but can’t be removed by surgery, or is spreading from the breast to other ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

Another option is MSD's immunotherapy Keytruda (pembrolizumab) and Eisai’s Lenvima (lenvatinib), which was also given the go-ahead in 2022. The new guidance says that the Cabometyx/Opdivo ...

For the most current information about the device indications for the therapeutic products in this group, go to: ...

Meanwhile, rival PD-1 inhibitor Keytruda (pembrolizumab ... line treatment as a combination with Eisai’s kinase inhibitor Lenvima (lenvatinib), with new data from the KEYNOTE-524 trial of ...

MI Cancer Seek is the first and only simultaneous Whole Exome and Whole Transcriptome-based assay with CDx indications for adults and pediatric patients IRVING, Texas, Nov. 6, 2024 /PRNewswire ...

MI Cancer Seek™ is the first FDA-approved test combining whole exome and transcriptome sequencing for solid tumor molecular profiling. The test identifies patients for targeted therapies in breast, ...

Nov. 7, 2024 — Researchers have developed an innovative technique to search for black hole light echoes. Their novel method, which will make it easier for the mass and the spin of black holes to ...

CENTRAL GOVERNMENT FUNDS: Social welfare would account for the largest portion of the NT$3.33 trillion budget, followed by spending on education, tech and culture ...